Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response

Haematologica

Volumn 97, Issue 6, 2012, Pages 835-841

  Aydinok, Yesim ^a   Evans, Patricia ^b   Manz, Chantal Y ^c   Porter, John B ^b  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Lipomed AG   (Switzerland)

Author keywords

Iron chelation; Non transferrin bound iron; Thalassemia major

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; IRON COMPLEX; NON TRANSFERRIN BOUND IRON; TRANSFERRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; EVENING DOSAGE; HUMAN; HUMAN TISSUE; IRON BALANCE; IRON CHELATION; LIVER BIOPSY; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA;

ADOLESCENT; BETA-THALASSEMIA; BLOOD PROTEINS; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; DEFEROXAMINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; LONGITUDINAL STUDIES; PROTEIN BINDING; PYRIDONES; YOUNG ADULT;

EID: 84862138030     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.056317     Document Type: Article

References (30)

1. Hershko C, Cook JD, Finch DA. Storage iron kinetics. 3. Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J Lab Clin Med. 1973;81(6):876-86.
2. Hershko C, Grady RW, Cerami A. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization. J Lab Clin Med. 1978;92(2):144-51.
3. Hershko C, Rachmilewitz EA. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Br J Haematol. 1979;42 (1):125-32.
4. Zevin S, Link G, Grady RW, Hider RC, Peter HH, Hershko C. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. Blood. 1992;79(1):248-53.
5. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97(4): 1115-22.
6. Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood. 1982;60(2):288-94.
7. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 1990;336 (8726):1275-9.
8. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood. 1994;83(8):2329-33.
9. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007;92(12):1599-606.
10. Hershko C, Peto TE. Non-transferrin plasma iron. Br J Haematol. 1987;66(2):149-51.
11. Evans RW, Rafique R, Zarea A, Rapisarda C, Cammack R, Evans PJ, et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem. 2008;13(1):57-74.
12. Silva AM, Hider RC. Influence of nonenzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrinbound iron speciation. Biochim Biophys Acta. 2009;1794(10):1449-58.
13. Silva AM, Kong X, Parkin MC, Cammack R, Hider RC. Iron(III) citrate speciation in aqueous solution. Dalton Trans. 2009;(40): 8616-25.
14. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin-bound iron. Anal Biochem. 1990;186 (2):320-3.
15. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88(2):705-13.
16. Taher A, Musallam KM, El Rassi F, Duca L, Inati A, Koussa S, Cappellini MD. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol. 2009;146(5): 569-72.
17. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of nontransferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem. 1999;273(2):212-20.
18. Jacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, et al. Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Anal Biochem. 2005;341(2):241-50.
19. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102(7):2670-7.
20. Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res. 2010;156(2):55-67.
21. Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, et al. Inflammation and oxidant-stress in betathalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica. 2008; 93(6):817-25.
22. al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89(2):403-8.
23. Robbins DA. Methods for Biological Monitoring. 1988; chap 118: 223-7.
24. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000; 343(5):327-31.
25. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in c-thalassemia major. Blood. 2008;111(2):583-7.
26. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18(2):277-87.
27. Zanninelli G, Breuer W, Cabantchik ZI. Daily labile plasma iron as an indicator of chelator activity in thalassaemia major patients. Br J Haematol. 2009;147(5):744-51.
28. al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol. 1992;82 (2):431-436.
29. Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in ironoverloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood. 2004;104(5):1504-10.
30. Rienhoff HY Jr, Viprakasit V, Tay L, Harmatz P, Vichinsky E, Chirnomas D, et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica. 2011;96(4):521-5.